KCT0007622
Not yet recruiting
未知
SGLT2 inhibitor versus DPP-4 inhibitor on left ventricular ejection fraction measuredby echocardiography in diabetic patients with acute myocardial infarction and midranged ejection fraction (EMPA-MI-MREF)
ConditionsDiseases of the circulatory system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the circulatory system
- Sponsor
- Chonnam National University Hospital
- Enrollment
- 600
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) 19 years of age or older
- •2\) Left ventricular ejection fraction of 40\~49% in echocardiography performed within 30 days of diagnosis of acute myocardial infarction
- •3\) Those diagnosed with type 2 diabetes and covered by SGLT2 inhibitor and DPP4 inhibitor insurance \-\> If metformin is stably administered for at least 12 weeks before participating in the trial and the HbA1c is 7\.0% or higher, or If you are taking the second diabetes drug (Metformin \+ \[sulfonylurea, Meglitinide, alpha\-glucodase inhibitor, Thiazolidinedione, DPP4 inhibitor])
- •4\) When consent to participate in clinical trial
Exclusion Criteria
- •1\) Patients with hypersensitivity to SGLT\-2 inhibitors
- •2\) Patients taking SGLT\-2 inhibitors continuously
- •3\) Patients with type 1 diabetes or those who need insulin supply
- •4\) glomerular filtration rate (eGFR) \<45 mL/min/1\.73m 2 (MDRD formula), patients with end stage renal disease (ESRD) or patients on dialysis
- •5\) Patients with severe liver dysfunction including cirrhosis patients (hepatic enzyme levels more than 3 times the upper limit of normal)
- •6\) Patients who are taking drugs that can significantly affect blood sugar control (such as systemic corticosteroids) or are expected to take them during the trial period
- •7\) Women of childbearing potential who has a plan to become pregnant during clinical trials, or do not intend to use appropriate contraceptive methods
- •8\) Subjects who visited the hospital for cardiac arrest or cardiogenic shock before randomization, and whose survival is judged to be low.
- •9\) Persons diagnosed with heart failure before randomization
- •10\) You are participating in another randomized controlled study, or you are participating in an observational study that may affect the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Comparison of SGLT2 inhibitors versus DPP-4 inhibitors for diabetic macular edemaType 2 diabetes mellitusJPRN-UMIN000015873Yokohama City University Medical Center30
Terminated
Not Applicable
Combination of SGLT2 inhibitor and DPP-4 inhibitor as add-on therapy in subjects with type 2 diabetes inadequately controlled on insulin combined with metformin + DPP-4 inhibitor or metformin + SGLT2 inhibitor or metformin : open-label, multicenter trialKCT0004959Korea University Anam Hospital102
Completed
Not Applicable
The differecnces between SGLT2 and DPP4 inhibitors in blood glucose management and cardiac sympathetic nerve activityDiabetes mellitus (DM) patients complicated with heart failure (HF)JPRN-UMIN000032277Toho University40
Completed
Not Applicable
Effects of combined SGLT2 inhibitor and DPP-4 inhibitor therapy on advanced glycation end productsType 2 diabetesJPRN-UMIN000049408Akishima Clinic35
Completed
Not Applicable
Effects of DPP4 inhibitor, sitagliptin or Sulfonylurea on intrahepatic adipose mass and lipid metabolism in patients with type 2 diabetes accompanied by fatty liver : a prospective randomized, open-label trialType 2 diabetesJPRN-UMIN000013356St.Marianna University School of Medicine60